Overview

Efficacy and Safety of Canagliflozin (TA-7284) in Patients With Diabetic Nephropathy

Status:
Completed
Trial end date:
2021-01-21
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of Canagliflozin (TA-7284) in Japanese patients with Diabetic Nephropathy, compared with placebo
Phase:
Phase 3
Details
Lead Sponsor:
Mitsubishi Tanabe Pharma Corporation
Treatments:
Canagliflozin